These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32584980)

  • 1. All about clinical trial course: one of the masterpieces of the European Society of Cardiology-Working Group on Cardiovascular Pharmacotherapy educational programme.
    Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):275-276. PubMed ID: 32584980
    [No Abstract]   [Full Text] [Related]  

  • 2. European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition.
    Atar D
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):3-4. PubMed ID: 28062654
    [No Abstract]   [Full Text] [Related]  

  • 3. Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
    Lewis BS; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):3-4. PubMed ID: 27533055
    [No Abstract]   [Full Text] [Related]  

  • 4. The application to MEDLINE from European Heart Journal-Cardiovascular Pharmacotherapy has been accepted!
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):207-8. PubMed ID: 27600901
    [No Abstract]   [Full Text] [Related]  

  • 5. Reporting of sex-specific outcomes in trials of interventions for cardiovascular disease: Has there been progress?
    Schreuder MM; Boersma E; Kavousi M; Visser LE; Roos-Hesselink JW; Versmissen J; Roeters van Lennep JE
    Maturitas; 2021 Feb; 144():1-3. PubMed ID: 33358200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Heart Journal - Cardiovascular Pharmacotherapy: now accepted for an official Impact Factor.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):59. PubMed ID: 30874813
    [No Abstract]   [Full Text] [Related]  

  • 7. European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):183-184. PubMed ID: 31531677
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety in clinical trials in cardiovascular disease.
    Cohn JN
    J Am Coll Cardiol; 2006 Aug; 48(3):430-3. PubMed ID: 16875964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Schmidt M; Lamberts M; Olsen AM; Fosbøll EL; Niessner A; Tamargo J; Rosano G; Agewall S; Kaski JC; Kjeldsen K; Lewis BS; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):108-18. PubMed ID: 27533522
    [No Abstract]   [Full Text] [Related]  

  • 10. Old and new drugs in cardiovascular pharmacotherapy.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):1-2. PubMed ID: 30615170
    [No Abstract]   [Full Text] [Related]  

  • 11. [The efficacy and safety of the drug treatment of cardiovascular diseases].
    Mazur NA
    Ter Arkh; 1993; 65(8):4-7. PubMed ID: 8211800
    [No Abstract]   [Full Text] [Related]  

  • 12. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.
    Torok RD; Li JS; Kannankeril PJ; Atz AM; Bishai R; Bolotin E; Breitenstein S; Chen C; Diacovo T; Feltes T; Furlong P; Hanna M; Graham EM; Hsu D; Ivy DD; Murphy D; Kammerman LA; Kearns G; Lawrence J; Lebeaut B; Li D; Male C; McCrindle B; Mugnier P; Newburger JW; Pearson GD; Peiris V; Percival L; Pina M; Portman R; Shaddy R; Stockbridge NL; Temple R; Hill KD
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440007
    [No Abstract]   [Full Text] [Related]  

  • 13. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes.
    Hoppe C; Kerr D
    Lancet Diabetes Endocrinol; 2017 Jan; 5(1):13. PubMed ID: 28010783
    [No Abstract]   [Full Text] [Related]  

  • 14. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
    Landmesser U; Chapman MJ; Farnier M; Gencer B; Gielen S; Hovingh GK; Lüscher TF; Sinning D; Tokgözoglu L; Wiklund O; Zamorano JL; Pinto FJ; Catapano AL; ;
    Eur Heart J; 2017 Aug; 38(29):2245-2255. PubMed ID: 27789571
    [No Abstract]   [Full Text] [Related]  

  • 15. President's Page: ISCP's educational goals.
    Cohn JN
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):89. PubMed ID: 20112058
    [No Abstract]   [Full Text] [Related]  

  • 16. [Interactions of cardiac and antiretroviral medication].
    Egger S; Drewe J
    Herz; 2005 Sep; 30(6):493-503. PubMed ID: 16170680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular pharmacotherapy in the aged].
    Baumhäkel M; Böhm M
    Internist (Berl); 2003 Aug; 44(8):943-50. PubMed ID: 14671808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partition testing in confirmatory adaptive designs with structured objectives.
    Sugitani T; Hamasaki T; Hamada C
    Biom J; 2013 May; 55(3):341-59. PubMed ID: 23576221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance?
    Willenheimer R; Dahlöf B; Gordon A
    Heart; 2000 Aug; 84(2):129-33. PubMed ID: 10908243
    [No Abstract]   [Full Text] [Related]  

  • 20. Statistical challenges in a regulatory review of cardiovascular and CNS clinical trials.
    Hung HM; Wang SJ; Yang P; Jin K; Lawrence J; Kordzakhia G; Massie T
    J Biopharm Stat; 2016; 26(1):37-43. PubMed ID: 26366624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.